Navigation Links
Regeneron Reports First Quarter 2013 Financial and Operating Results
Date:5/3/2013

1b trials with dupilumab (REGN668), an antibody targeting IL-4R, in atopic dermatitis were presented at the 71st Annual Meeting of the American Academy of Dermatology in March 2013.  Data from a Phase 2a trial of dupilumab in allergic asthma will be presented at the American Thoracic Society meeting in May 2013.  Dupilumab is being developed in collaboration with Sanofi.

First Quarter 2013 Financial ResultsTotal Revenues: Total revenues were $440 million in the first quarter of 2013, compared to $232 million in the first quarter of 2012.  Total revenues include collaboration revenues of $114 million in the first quarter of 2013, compared to $97 million in the first quarter of 2012. 

Product Revenues: Net product sales were $319 million in the first quarter of 2013, compared to $128 million in the first quarter of 2012.  EYLEA net product sales were $314 million in the first quarter of 2013, compared to $124 million in the first quarter of 2012.  ARCALYST net product sales were $5 million in the first quarter of 2013, compared to $4 million in the first quarter of 2012.  

Research and Development (R&D) Expenses: GAAP R&D expenses were $180 million in the first quarter of 2013, compared to $139 million in the first quarter of 2012.  The higher R&D expenses in 2013 were principally due to increased R&D headcount and activities, primarily related to the Company's antibody collaboration with Sanofi, and higher non-cash share-based compensation expense.  In the first quarter of 2013, R&D related non-cash share-based compensation expense was $27 million, compared to $11 million in the first quarter of 2012.

Selling, General, and Administrative (SG&A) Expenses: GAAP SG&A expenses were $77 million in the first quarter of 2013, compared to $58 million in the first quarter of 2012.  The increase was primarily due to higher expenses in connection with
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
2. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Regeneron Announces March 2012 Investor Conference Presentations
5. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
6. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
7. Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results
8. PAREXEL International Reports Third Quarter Fiscal Year 2013 Results
9. Cytos Biotechnology Ltd Reports First Quarter 2013 Financial Results and Recent Development
10. InterMune Reports First Quarter 2013 Financial Results and Business Highlights
11. Cord Blood Banking Industry: 2013 Growth Opportunities Analysis in New Market Research Report at ReportsnReports.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Women in the ... to an additional family planning option. Sayana® Press ... at all levels of the health system and ... a widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with ... is the first of four African countries expected ...
(Date:7/10/2014)... 10, 2014 Unraveling life’s mysteries can ... The Archer Family purchased a DNA test ... ended up with a lifetime of memories, sharing, and ... family members’ DNA genuinely brought the family closer together. ... deeper into genetic history and prior to taking the ...
(Date:7/10/2014)... POINT, Ind. , July 10, 2014 ... expanded its use of capnography for respiratory ... growing group of healthcare leaders in embracing ... measures how effectively patients are breathing and ... depression occurs. By measuring the amount of ...
(Date:7/10/2014)... 2014   Ceres, Inc . (Nasdaq: ... today financial results for the three months ended May ... Ceres reported that the company and its ... growing season in Brazil, which concluded in June, despite ... evaluation areas for part of the growing season. Yields ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... Singapore and Washington DC (July 27, 2009) According to ... Decision Making , a large-scale, covert anthrax attack on ... an extremely effective public health response, primarily because of ... response to it. The article "Predicting Hospital Surge ...
... , TARRYTOWN, N.Y., Aug. 14 /PRNewswire/ -- ... for Diabetic Patients and their Caregivers on August 13, stating that ... high (elevated) blood glucose result." Since 2006, Bayer Diabetes Care ... quinone) glucose monitoring technology for its blood glucose meters. ...
... HARBIN, China, Aug. 14 /PRNewswire-Asia-FirstCall/ -- China Sky One,Medical, ... CSKI ), a,leading fully integrated pharmaceutical company in the ... the second quarter,of 2009. , , Second ... 35.5% year-over-year to $32.2 million, -- Gross ...
Cached Biology Technology:Bioterrorism and disaster preparedness explored in special issue of Medical Decision Making 2China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 2China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 3China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 4China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 5China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 6China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 7China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 8China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 9China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 10China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results 11
(Date:7/11/2014)... OAK RIDGE, Tenn., July 11, 2014--Researchers at the ... received eight R&D 100 awards, presented by R&D ... innovations. , "These awards recognize the tremendous ... Energy Ernest Moniz. "Research and development at the ... its energy challenges and pursue the scientific and ...
(Date:7/11/2014)... There were many fires burning in eastern New South ... July 11. , At 03:35 UTC on July 11 ... when Aqua passed over eastern New South Wales (NSW), ... natural-color visible image of the region and spotted smoke ... by MODIS,s thermal bands, are outlined in red. , ...
(Date:7/11/2014)... Canyon fire started near the City of Entiat on ... resources, the fire quickly grew to over 1,000 acres ... the fire is under investigation by the Washington Department ... with existing local resources in developing fire control strategies ... (USFS), Washington State Department of Natural Resources, (WA DNR), ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... Va. Researchers have unveiled the evolutionary origin ... species of Agrobacterium. A comprehensive comparison of the ... other bacteria suggests a general model for how ... are members of the Rhizobiaceae family, which also ...
... about house calls! The Wildlife Conservation Society thanks The ... campaign for their assistance in performing a brain scan ... The on-site procedureperformed by dozens of wildlife veterinarians, zookeepers, ... the Bobby Murcer Mobile MRI Unit, a 48-foot-long MRI ...
... a network of tiny sensors as small as dewdrops called ... Scattered outdoors on rocks, fence posts and doorways, or ... a completely new and cost-effective system for safeguarding and securing ... Tel Aviv University Faculty of Engineering team drew upon the ...
Cached Biology News:Evolutionary origin of bacterial chromosomes revealed 2Gorilla gets MRI at Bronx Zoo 2Gorilla gets MRI at Bronx Zoo 3Intruder alert: Tel Aviv University's 'Smart Dew' will find you! 2
... In virtually every research laboratory, the ... of information accurately, inexpensively and in real ... compact lab analysis system includes the Luminex ... It utilizes xMAP technology which enables you ...
... of amino acids and peptides produced ... It is recommended for laboratory media ... in antibiotics, toxins and enzyme productions. ... pH6.8 0.5 at 25 C, 2% ...
... G2 cells were cultured in Minimum Essential Medium ... the log phase of growth. In order ... cells were fixed in acetone-methanol. The cells ... coated slide, with each wells surface specifically treated ...
... cultured in Minimum Essential Medium (Eagle) with 2 ... of growth. In order to keep the ... in acetone-methanol. The cells are arrayed on ... each wells surface specifically treated to enhance cellular ...
Biology Products: